Recent News Releases

Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit...

ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category....